Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q92997
UPID:
DVL3_HUMAN
Alternative names:
DSH homolog 3
Alternative UPACC:
Q92997; B4E3E5; D3DNT0; O14642; Q13531; Q8N5E9; Q92607
Background:
Segment polarity protein dishevelled homolog DVL-3, also known as DSH homolog 3, plays a pivotal role in the Wnt signaling pathway. This pathway is crucial for cell fate determination, cell migration, and embryonic development. The protein's involvement in multiple Wnt genes' signal transduction underscores its significance in these biological processes.
Therapeutic significance:
DVL-3 is linked to Robinow syndrome, autosomal dominant 3, a rare skeletal dysplasia syndrome. This connection highlights the protein's potential as a target for therapeutic intervention in treating skeletal and developmental anomalies associated with this condition.